Fairvalue-Calculator Fairvalue-Calculator
EN DE

Omada Health, Inc (OMDA) Fair Value & Analysis

Healthcare · US · Market cap $1.0B

Price$18.30
Fair Value$17.39
Upside-5.0%
Quality91/100
Evidence: Medium Range $13.04 – $21.73

Fair value as of: Jun 24, 2026

Analysis

Omada Health, Inc (OMDA) currently trades at $18.30, while our model-based Fair Value estimate is $17.39 — implying the stock looks roughly 5.0% overvalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Omada Health, Inc., together with its subsidiary, Physera, Inc., provides a range of virtual care programs in the United States. The company offers cardiometabolic programs for prediabetes, diabetes, and hypertension; a physical therapy program to address musculoskeletal conditions; other support programs for members taking glucagon-like peptide-1 agonists in its cardiometabolic program; and weight management programs, as well as various behavioral health support programs. It also delivers virtual care. The company offers its programs for employers, health plans and systems, and pharmacy benefits managers through its direct sales force and channel partners. The company was incorporated in 2011 and is headquartered in South San Francisco, California.

Open the full interactive analysis →

Similar stocks

Frequently asked questions

Is Omada Health, Inc (OMDA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $17.39 versus a price of $18.30 — about −5% (overvalued). Model-based estimate, not financial advice.
What is the fair value of OMDA?
Our 21-model fair value for Omada Health, Inc is $17.39 (as of Jun 24, 2026), built from audited fundamentals. The current price is $18.30.
What is the quality score of OMDA?
Omada Health, Inc has a Quality Score of 91/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.